comparemela.com

Latest Breaking News On - Strategy after - Page 1 : comparemela.com

Atezolizumab/Cabozantinib Fails to Elicit Benefit Over SOC in Second-line Metastatic NSCLC

Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.

In Second-Line, Atezolizumab/Cabozantinib Shows No Benefit Over SOC in NSCLC

At the 2023 European Lung Cancer Congress, results from the recent findings of the CONTACT-01 trial showed no benefit for patients with metastatic non–small cell lung cancer on the combination of atezolizumab and cabozantinib compared with the standard of care.

EQS-Adhoc: Zug Estates Holding AG: Zug Estates mit sehr robustem Halbjahresergebnis trotz Pandemie

ياسر عبيدو يكتب: الرابح طالبان أم أمريكا

ياسر عبيدو يكتب: الرابح طالبان أم أمريكا
elbalad.news - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elbalad.news Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.